Hematology News

Several hematologists will be honored during this year’s ASH Annual Meeting, scheduled for Dec. 9-12 in San Diego.

The FDA approved the first two cell-based gene therapies for treatment of sickle cell disease.

Direct oral anticoagulants have become the standard of care for stroke prevention in patients with atrial fibrillation, among other indications, but factor XI/XIa inhibitors may have the potential to usurp them due to safety profiles.

The FDA approved iptacopan for treatment of adults with paroxysmal nocturnal hemoglobinuria.

Three physicians have been elected to serve in leadership roles on ASH’s executive committee.

President Joe Biden today announced his intention to appoint oncologist, researcher and educator, W. Kimryn Rathmell, MD, PhD, as director of the NCI.

Elderly individuals with moderate or severe hemophilia had poorer joint or functional status and greater joint pain sensitivity than those with mild hemophilia or healthy controls, according to study results.

PHILADELPHIA — In a phase 2b trial, abelacimab, a novel factor XI inhibitor, drastically reduced bleeding compared with rivaroxaban in patients with atrial fibrillation requiring stroke prevention.

PHILADELPHIA — In patients with acute MI and anemia, there was no difference between liberal and restrictive transfusion strategies for the composite outcome of death and MI at 30 days, according to results of the MINT trial.

NASHVILLE, Tenn. — Venous tumor thrombus appeared associated with elevated rates of pulmonary metastasis among patients with clear cell renal cell carcinoma, according to study results.